IMRX ▲ +1.5% - Immuneering Corporation $IMRX - Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival Immuneering Corporation rose 1.5% on news that the company will present at the AACR Conference on Pancreatic Cancer, showcasing clinical data for its candidate drug atebimetinib and its dual mechanism of action aimed at extending survival in pancreatic cancer patients. Investor optimism around the presentation of positive efficacy data for a late-stage cancer therapy candidate typically supports biotech stock gains. 10-SEP-2026 07:30 AM ET